Rationale for the major changes in the pharmacotherapy section of the National Asthma Education and Prevention Program guidelines

Journal of Allergy and Clinical Immunology

Volumn 120, Issue 5, 2007, Pages 989-994

  Kelly, H William ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

adverse effects; Asthma; childhood asthma; inhaled corticosteroids; long acting inhaled 2 agonists; omalizumab; pediatrics; treatment guidelines

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GOLD SALT; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; IPRATROPIUM BROMIDE; LEVALBUTEROL; LONG ACTING DRUG; MACROLIDE; METHOTREXATE; MOMETASONE FUROATE; MONTELUKAST; OMALIZUMAB; PLACEBO; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; THEOPHYLLINE; ZAFIRLUKAST; ZILEUTON;

ADJUVANT THERAPY; ASTHMA; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE EXACERBATION; DOSE CALCULATION; DOSE RESPONSE; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRY POWDER; GROUPS BY AGE; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; LOW DRUG DOSE; MEDICAL EXPERT; METERED DOSE INHALER; MONOTHERAPY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SPIROMETRY; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; MALE; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 35648984573     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2007.01.035     Document Type: Review

References (61)

1. National Heart, Lung and Blood Institute. National Asthma Education and Prevention Program, Expert Panel Report 3. Guidelines for the diagnosis and management of asthma (2006), US Department of Health and Human Services, Bethesda (MD) National Institutes of Health publication no. 07-4051
2. National Heart, Lung and Blood Institute. National Asthma Education and Prevention Program, Expert Panel Report 2. Guidelines for the diagnosis and management of asthma (1997), US Department of Health and Human Services, Bethesda (MD) National Institutes of Health publication no. 97-4051
3. US Food and Drug Administration. Center for Drug Evaluation and Research, Pediatric Drug Development. Available at: http://www.fda.gov/cder/pediatric/index/htm. Accessed November 19, 2006.
4. US Food and Drug Administration. Guidance for industry: E11 clinical investigation of medicinal products in the pediatric population. Available at: http://www.fda.gov/cder/guidance/index.htm. Accessed November 19, 2006.
5. Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 343 (2000) 1054-1063
6. Guilbert T.W., Morgan W.J., Zeiger R.S., Mauger D.T., Boehmer S.J., Szefler S.J., et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 354 (2006) 1985-1997
7. Knorr B., Franchi L.M., Bisgaard H., Vermeulen J.H., LeSouef O., Santanello N., et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 108 (2001) E48
8. Qaquindah P.Y., Sugerman R.W., Ceruti E., Maspero J.F., Kleha J.F., Scott C.A., et al. Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study. J Pediatr 149 (2006) 663-670
9. Amirav I., Newhouse M.T., and Mansour Y. Measurement of peak inspiratory flow with In-Check Dial Device to stimulate low-resistance (Diskus) and high-resistance (Turbuhaler) dry powder inhalers in children with asthma. Pediatr Pulmonol 39 (2005) 447-451
10. Dolovich M.B., Ahrens R.C., Hess D.R., Anderson P., Dhand R., Rau J.L., et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest 127 (2005) 335-371
11. Wildhaber J.H., Dore N.D., Wilson J.M., Devadason S.G., and LeSouef P.N. Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr 135 (1999) 28-33
12. Bisgaard H. Delivery of inhaled medication to children. J Asthma 34 (1997) 443-467
13. Strunk R.C., and Bloomberg G.R. Omalizumab for asthma. N Engl J Med 354 (2006) 2689-2695
14. Djukanovic R., Wilson S.J., Kraft M., Jarjour N.N., Steel M., Chung K.F., et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170 (2004) 583-593
15. Busse W., Corren J., Lanier B.Q., McAlary M., Fowler-Taylor A., Cioppa G.D., et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108 (2001) 184-190
16. Soler M., Matz J., Townley R., Buhl R., O'Brien J., Fox H., et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18 (2001) 254-261
17. Milgrom H., Berger W., Nayak A., Gupta N., Pollard S., McAlary M., et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 108 (2001) E36
18. Holgate S.T., Chuchalin A.G., Hebert J., Lotvall J., Persson G.B., Chung K.F., et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 34 (2004) 632-638
19. Vignola A.M., Humbert M., Bousquet J., Boulet L.P., Hedgecock S., Blogg M., et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 59 (2004) 709-717
20. Ayres J.G., Higgins B., Chilvers E.R., Ayre G., Blogg M., and Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 59 (2004) 701-708
21. Humbert M., Beasley R., Ayres J., Slavin R., Hebert J., Bousquet J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60 (2005) 309-316
22. Robinson D.S., Campbell D., and Barnes P.J. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 357 (2001) 2007-2011
23. National Institutes of Health; National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics 2002. J Allergy Clin Immunol 110 suppl (2002) S142-S219
24. US Food and Drug Administration. Medical officer review. Provided for meeting of Pulmonary-Allergy Drugs Advisory Committee, July 13, 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/. Accessed March 11, 2006.
25. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., Dorinsky P.M., and SMART study group. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 (2006) 15-26
26. Mann M., Chowdhury B., Sullivan E., Nicklas R., Anthracite R., and Meyer R.J. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 124 (2003) 70-74
27. Murphy S., and Roberts R. "Black box" 101: how the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk. J Allergy Clin Immunol 117 (2006) 34-39
28. Martinez F.D. Safety of long-acting beta-agonists-an urgent need to clear the air. N Engl J Med 353 (2005) 2637-2639
29. Nelson H.S. Is there a problem with inhaled long-acting β-adrenergic agonists. J Allergy Clin Immunol 117 (2006) 3-16
30. Salpeter S.R., Buckley N.S., Ormiston T.M., and Salpeter E.E. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 144 (2006) 904-912
31. Matz J., Emmett A., Rickard K., and Kalberg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. J Allergy Clin Immunol 107 (2001) 783-789
32. Ni Chroinin M., Greenstone I.R., and Ducharme F.M. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults. Cochrane Database Syst Rev (2004) CD005307
33. Sin D.D., Man J., Sharpe H., Gan W.Q., and Man S.F. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA 292 (2004) 367-376
34. Masoli M., Weatherall M., Holt S., and Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 60 (2005) 730-734
35. Bateman E.D., Boushey H.A., Bousquet J., Busse W.W., Clark T.J.H., Pauwels R.A., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 170 (2004) 836-844
36. 2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol 36 (2003) 391-398
37. 2 agonist monotherapy vs. continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 285 (2001) 2583-2593
38. Lemanske Jr. R.F., Sorkness C.A., Mauger E.A., Lazarus S.C., Boushey H.A., Fahy J.V., et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 285 (2001) 2594-2603
39. Castle W., Fuller R., Hall J., and Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 306 (1993) 1034-1037
40. 2-agonists in asthma: an overview of Cochrane systematic reviews. Respir Med 99 (2005) 384-395
41. Salpeter S.R., Ormiston T.M., and Salpeter E.E. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med 140 (2004) 802-813
42. 2-agonists. Pharmacotherapy 26 suppl (2006) 164S-174S
43. Inman M.D., and O'Byrne P.M. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med 153 (1996) 65-69
44. Ramage L., Lipworth B.J., Ingram C.G., Cree I.A., and Dhillon D.P. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 88 (1994) 363-368
45. 2 agonists. Thorax 56 (2001) 529-535
46. Haney S., and Hancox R.J. Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial. Respir Res 6 (2005) 107
47. Jones S.L., Cowan J.O., Flannery E.M., Hancox R.J., Herbison G.P., and Taylor D.R. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. Eur Respir J 17 (2001) 368-373
48. Korosec M., Novak R.D., Myers E., Skowronski M., and McFadden Jr. E.R. Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. Am J Med 107 (1999) 209-213
49. Tattersfield A.E., Postma D.S., Barnes P.J., Svensson K., Bauer C.A., and O'Byrne P.M. Exacerbations of asthma-a descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med 160 (1999) 594-599
50. 2 agonists: issues in the management of asthma. Ann Pharmacother 39 (2005) 931-938
51. 2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 162 (2000) 75-80
52. Taylor D.R., Drazen J.M., Herbison G.P., Yandava C.N., Hancox R.J., and Town G.I. Asthma exacerbations during long term beta agonist use: influence of β2 adrenoceptor polymorphism. Thorax 55 (2000) 762-767
53. Israel E., Chinchilli V.M., Ford J.G., Boushey H.A., Cherniak R., Craig T.J., et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomized, placebo-controlled cross-over trial. Lancet 364 (2004) 1505-1512
54. Wechsler M.E., Lehman E., Lazarus S.C., Lemanske R.F., Boushey H.A., Deykin A., et al. β-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 173 (2006) 519-526
55. Lee D.K., Currie G.P., Hall I.P., Lima J.J., and Lipworth B.J. The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol 57 (2004) 68-75
56. 2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 118 (2006) 809-816
57. 2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 61 (2006) 940-944
58. Mann R.D., Kubota K., Pearce G., and Wilton L. Salmeterol: a study by prescription event monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol 49 (1996) 247-250
59. Anderson H.R., Ayres J.G., Sturdy P.M., Bland J.M., Butland B.K., Peckitt C., et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 330 (2005) 117
60. O'Byrne P.M., Barnes P.J., Rodriguez-Roisin R., Runnerstrom E., Sandstrom T., Svensson K., et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 164 (2001) 1392-1397
61. Minino AM, Heron MP, Smith BL. Deaths: preliminary data for 2004. National Vital Statistics Reports. Vol 54, No. 19, June 28, 2006. Available at: www.cdc.gov/nchs. Accessed January 4, 2007.